TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02005289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MOR00208
Description: Given by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MOR00208
Description: Given by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
Study: NCT00183547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living in Harmony depression prevention program
Description: Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression-prevention education and support
Description: Weekly therapy sessions offering general depression-prevention education and support
Study: NCT03142477

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.
Study: NCT04413357

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced Nutritional Drink
Description: Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as Supplemental Nutrition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Specific, Balanced Nutritional Drink (DMA)
Description: Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition available in retail setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Specific, Balanced Nutritional Drink DMB
Description: Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition.
Study: NCT02568410

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting using cardiopulmonary bypass
Description: no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
Study: NCT03916055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP)
Description: The intervention consists of 10 modules/chapters for children/adolescents, delivered over 10. Each of the 10 modules includes age-appropriate texts, animations and exercises. The intervention is primarily based on ERP techniques. During the treatment, participants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their caregiver/parent, the participant is instructed to provoke premonitory urges (a sensation usually felt before a tic is expressed), while still suppressing tics, which is known as 'exposure'.~The parent is provided with her/his own separate login to the internet platform, which consists of 10 separate modules/chapters. The parent intervention consists mainly of information regarding parent coping strategies, social support and functional analysis relating to tics. Both the child/adolescent and the parent have individual access to the same therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on tics
Description: The active comparator is designed to match the experimental intervention in all aspects except for the module content (same platform, same treatment length, same therapist support etc.). The intervention consists mainly of psychoeducational information about TD/PTD and common comorbid conditions, and reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors, strategies for describing tics to other people, among others. Problem-solving and development of expertise in tic disorders is emphasised. The intervention does not include any information on ERP or functional analysis and interventions.~As in the experimental intervention, the parent is provided with her/his own separate login to the internet platform. The parent intervention consists mainly of information regarding parent coping strategies and social support. Both the child and the parent have individual access to the same therapist.
Study: NCT02477462

Intervention type: OTHER
Intervention: Clinic visit
Description: Blood draw every 3 months; quality of life surveys and imaging annually

Intervention type: OTHER
Intervention: Baseline visit
Description: Blood draw and quality of life surveys
Study: NCT03205696

Intervention type: DRUG
Intervention: Antiretrovirals
Description: The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults

Intervention type: DRUG
Intervention: Antiretrovirals
Description: The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
Study: NCT00666367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cure
Description: 4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
Study: NCT02984397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen Fumarate
Description: Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT03828305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and creation of the Network-CPR
Description: Training and creation of the Network-CPR that will cover the city. This network will be created with certain population groups that are routinely in contact with susceptible persons of OHCA (police, firemen, teaching staff, health personnel, merchants, pharmacists, university students, etc.), in addition, relatives of people with heart disease will be included. In the case of elderly people who are alone, they will include their neighbors or caregivers. In the city, there are 2,105 people with heart disease susceptible to OHCA. The research team and the health personnel of the participating primary care centers (PCC) will offer training courses on basic CPR maneuvers and use of the AED, following the protocol of the Center Català de Ressucitació (CCR). The training is aimed at training 430 people (20% of the relatives of people with heart disease) and will be made by trainers accredited by the CCR. There will be a total of 30 sessions with groups of approximately 15 people.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No intervention
Study: NCT04502771

Intervention type: DRUG
Intervention: Antifungal treatment
Description: Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit
Study: NCT01388101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing antibody probing system (e- Ab sensor)
Description: Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
Study: NCT02317523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information and Support
Description: Six face-to-face sessions (60 minutes each) of Supportive Therapy
Study: NCT02002949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short daily hemodialysis
Description: 5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemodialysis
Description: 3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
Study: NCT02074982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab 45/90 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo secukinumab
Description: Placebo
Study: NCT01408836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Description: Plasma exchange

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous methyl prednisolone
Description: Intravenous methyl prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl prednisolone
Description: methyl prednisolone
Study: NCT04298008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg iv on D1 Every 4 weeks
Study: NCT02267655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled Nitric Oxide - 30 mcg/kg IBW/hr
Description: inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr
Description: inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inhaled nitric oxide 75 mcg/kg IBW/hr
Description: inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nitric oxide 75 mcg/kg IBW/hr
Description: inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
Study: NCT00441337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1106
Description: patients will receive a single dose of MDX-1106 as a 60 minute infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1106
Description: patients will receive a single dose of MDX-1106 as a 60 minute infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1106
Description: patients will receive a single dose of MDX-1106 as a 60 minute infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1106
Description: patients will receive a single dose of MDX-1106 as a 60 minute infusion.
Study: NCT00654849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmakinetic bipolar energy forceps
Description: Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Hysterectomy with traditional suture technique
Description: The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
Study: NCT03830502

Intervention type: PROCEDURE
Intervention: Surgical sterilization
Description: Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique

Intervention type: PROCEDURE
Intervention: Surgical sterilization
Description: Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
Study: NCT04682600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liver Incytes System
Description: The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method. The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them. A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver. Ultrasound imaging through the patient ribs is used to track the displacements of these waves. Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated. The use of volumetric multi-frequency imaging increases the amount of liver scanned
Study: NCT01162629

Intervention type: DEVICE
Intervention: Osteon bone graft
Description: Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
Study: NCT03073616

Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasound and chest RX
Study: NCT01788501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: D-1\~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20\~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: D-1\~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20\~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
Study: NCT02760394

Intervention type: DEVICE
Group type: OTHER
Intervention: HBOT
Description: 40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HBOT
Description: 40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
Study: NCT02810834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking/Running program
Description: Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).~The intervention will run over two school years (approximately 16 months)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom physical activity break program
Description: Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.~The intervention will run over two school years (approximately 16 months)
Study: NCT01905982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reflectory breathing therapy
Description: duration:2x60 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional breathing therapy
Description: duration:4x30 minutes
Study: NCT03668652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)
Description: HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy
Description: Prostatectomy arm:~Robot assisted or open retropubic prostatectomy
Study: NCT00653107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent insertion
Description: Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
Study: NCT01324375

Intervention type: DEVICE
Intervention: heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).
Description: pain during heat test preoperatively
Study: NCT04437394

Intervention type: DIAGNOSTIC_TEST
Intervention: flexible endoscopic evaluation of swallowing
Description: The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.

Intervention type: DIAGNOSTIC_TEST
Intervention: flexible endoscopic evaluation of swallowing
Description: The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.

Intervention type: DIAGNOSTIC_TEST
Intervention: The analysis of voice
Description: Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.

Intervention type: DIAGNOSTIC_TEST
Intervention: The analysis of voice
Description: Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.
Study: NCT03376997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: IV infusion
Study: NCT02723786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids
Description: This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
Study: NCT03376997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral tablet
Study: NCT01648309

Intervention type: OTHER
Intervention: Neuropsychological testing
Description: This is an observational study
Study: NCT03197220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fish
Description: 300 gr/week fish

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walnut
Description: 18 walnut per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fish-walnut
Description: 150 gr fish and 9 walnut per week
Study: NCT04155320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPART
Description: Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
Study: NCT00073671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention program
Description: Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants receive usual care